Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection

FEBS Journal

Volumn 279, Issue 8, 2012, Pages 1386-1397

  Stone, Trevor W ^a   Forrest, Caroline M ^a   Darlington, L Gail ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

Author keywords

kynurenic acid; kynurenine; neurodegeneration; neuroprotection; quinolinic acid; tryptophan

Indexed keywords

2 CARBOXY 5,7 DICHLORO 4 [[(N PHENYLAMINO)CARBONYL]AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; 3 (2 CARBOXY 4,6 DICHLORO 3 INDOLYL)PROPIONIC ACID; 3 NITROBENZOYLALANINE; 3,4 DICHLOROBENZOYLALANINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; 4 [(CARBOXYMETHYL)AMINO] 5,7 DICHLOROQUINOLINE 2 CARBOXYLIC ACID; 4 CARBOXYMETHYLAMINO 5,7 DICHLORO 2 QUINOLINECARBOXYLIC ACID; 4 HYDROXY 3 (CYCLOPROPYLCARBONYL) 7 CHLOROQUINOLINE 2 (1H) ONE; 5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 7 CHLORO 1,2,5,10 TETRAHYDRO 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,10 DIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; 7 CHLOROKYNURENIC ACID; FCE 28833A; INTERLEUKIN 1BETA; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; L 701252; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; OXYGENASE INHIBITOR; QUINOLINIC ACID; UNCLASSIFIED DRUG;

AMINO ACID BRAIN LEVEL; ATAXIA; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN MALARIA; CONVULSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MALARIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROKE; TRAUMATIC BRAIN INJURY; TRYPANOSOMIASIS;

ANIMALS; HUMANS; KYNURENINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84859610302     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08487.x     Document Type: Review

References (81)

1. Lapin IP, (1989) Behavioural and convulsant effects of kynurenines. In Quinolinic Acid and the Kynurenines (, Stone TW, ed.), pp. 193-211. CRC Press, Boca Raton, FL.
2. Stone TW, &, Perkins MN, (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72, 411-412.
3. Schwarcz R, Whetsell WO, &, Mangano RM, (1983) Quinolinic acid-an endogenous metabolite that produces axon-sparing lesions in rat-brain. Science 219, 316-318.
4. Guillemin GJ, (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279, 1356-1365.
5. Kandanearatchi A, &, Brew BJ, (2012) The kynurenine pathway and quinolinic acid: pivotal roles in HIV and associated neurocognitive disorders. FEBS J 279, 1366-1374.
6. Reference withdrawn.
7. Perkins MN, &, Stone TW, (1983) Quinolinic acid: regional variations in neuronal sensitivity. Brain Res 259, 172-176.
8. Stone TW, (2000) The development and therapeutic potential of kynurenic acid and kynurenine derivatives for CNS neuroprotection. Trends Pharmacol Sci 21, 149-154.
9. Stone TW, (2000) Inhibitors of the kynurenine pathway. Eur J Med Chem 35, 179-186.
10. Stone TW, &, Darlington LG, (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discovery 1, 609-620.
11. Stone TW, (2001) Kynurenines in the CNS-from obscurity to therapeutic importance. Prog Neurobiol 64, 185-218.
12. Rios C, &, Santamaria A, (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16, 1139-1143.
13. Santamaria A, Jimenez-Capdeville ME, Camacho A, Rodriguez-Martinez E, Flores A, &, Galvan-Arzate S, (1991) In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 12, 2693-2696.
14. Behan WMH, McDonald M, Darlington LG, &, Stone TW, (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 128, 1754-1760.
15. Stone TW, &, Behan WMB, (2007) Interleukin-1β but not TNF-α potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res 85, 1077-1085.
16. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, Binaglia M, Corsini E, Di Luca M, Galli CL, et al. (2003) Interleukin-1β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 34, 8692-8700.
17. Strijbos PJLM, &, Rothwell NJ, (1995) Interleukin-1β attenuates excitatory amino acid-induced neurodegneration in vitro- involvement of nerve growth factor. J Neurosci 15, 3468-3474.
18. Pelidou SH, Schultzberg M, &, Iverfeldt K, (2002) Increased sensitivity to NMDA receptor-induced excitotoxicity in cerebellar granule cells from interleukin-1 receptor type 1-deficient mice. J Neuroimmunol 133, 108-115.
19. Stone TW, Ceruti S, &, Abbracchio MP, (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. In Handbook of Experimental Pharmacology, Vol. 193: Adenosine Receptors in Health and Disease (, Wilson CN, &, Mustafa SJ, eds), ch. 17, pp. 535-589. Springer, Berlin.
20. Moffett JR, Espey MG, &, Namboodiri MAA, (1994) Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res 278, 461-469.
21. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, &, Markey SP, (1996) Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 320, 595-597.
22. Heyes MP, &, Nowak TS Jr, (1990) Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil. J Cereb Blood Flow Metab 10, 660-667.
23. Blight AR, Leroy EC Jr, &, Heyes MP, (1997) Quinolinic acid accumulation in injured spinal cord: time course, distribution, and species differences between rat and guinea pig. J Neurotrauma 14, 89-98.
24. Heyes MR, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mourdian MM, Sadler AE, Keilp J, et al. (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurologic status. Ann Neurol 29, 202-209.
25. Giorgini F, Guidetti P, Nguyen QV, Bennett SC, &, Muchowski PJ, (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37, 526-531.
26. Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, &, Darlington LG, (2010) Blood levels of kynurenines, interleukin IL-23 and sHLA-G at different stages of Huntington's disease. J Neurochem 112, 112-122.
27. Stone TW, (1993) The neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309-379.
28. Perkins MN, &, Stone TW, (1982) An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247, 184-187.
29. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, &, Albuquerque EX, (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci 21, 7463-7473.
30. Stone TW, (2007) Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur J Neurosci 25, 2656-2665.
31. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, &, Stone TW, (2007) Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 26, 2211-2221.
32. Pertovaara M, Raitala A, Lehtimaki T, Karhunen PJ, Oja SS, Jylha M, Hervonen A, &, Hurme M, (2006) Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Develop 127, 497-499.
33. Baran H, Kepplinger B, Herrera-Marschitz M, Stolze K, Lubec G, &, Nohl H, (2001) Increased kynurenic acid in the brain after neonatal asphyxia. Life Sci 69, 1249-1256.
34. Politi V, Deluca G, Gallai V, Puca O, &, Comin M, (1999) Clinical experiences with the use of indole-3-pyruvic acid. Adv Exp Med Biol 467, 227-232.
35. Luchowski P, &, Urbanska EM, (2007) SNAP and SIN-1 increase brain production of kynurenic acid. Eur J Pharmacol 563, 130-133.
36. Weiss G, Diez-Ruiz A, Murr C, Theurl I, &, Fuchs D, (2002) Tryptophan metabolites as scavengers of reactive oxygen and chlorine species. Pteridines 13, 140-144.
37. Giles GI, Collins CA, Stone TW, &, Jacob C, (2003) Electrochemical and in vitro evaluation of the redox properties of kynurenine species. Biochem Biophys Res Comm 300, 719-724.
38. Leipnitz G, Schumacher C, Dalcin KB, Scussiato K, Solano A, Funchal C, Dutra-Filho CS, Wyse ATS, Wannmacher CMD, Latini A, et al. (2006) In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem Int 50, 83-94.
39. Goldstein LE, Leopold MC, Huang XD, Atwood CS, Saunders AJ, Hartshorn M, Lim JT, Faget KY, Muffat JA, Scarpa RC, et al. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 39, 7266-7275.
40. Cozzi A, Carpenedo R, &, Moroni F, (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2YL]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 19, 771-777.
41. Murr C, Widner B, Wirleitner B, &, Fuchs D, (2002) Neopterin as a marker for immune system activation. Curr Drug Metab 3, 175-187.
42. Baran H, &, Schwarcz R, (1990) Presence of 3-hydroxyanthranilic acid in rat-tissues and evidence for its production from anthranilic acid in the brain. J Neurochem 55, 738-744.
43. Darlington LG, Forrest CM, Mackay GM, Stoy N, Smith RA, Smith AJ, &, Stone TW, (2010) On the biological significance of the 3-hydroxyanthranilic acid: anthranilic acid ratio. Int J Tryptophan Res 3, 51-59.
44. Weber WP, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, Schumacher R, Zajaz P, Misteli H, Frey DM, Oertli D, et al. (2006) Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8(+) T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol 36, 296-304.
45. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, &, Opelz G, (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196, 447-457.
46. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, &, Puccetti P, (2002) T cell apoptosis by tryptophan catabolism. Cell Death Diff 9, 1069-1077.
47. Lopez AS, Alegre E, LeMaoult J, Carosella E, &, Gonzalez A, (2006) Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol 43, 2151-2160.
48. Miche H, Brumas V, &, Berthon G, (1997) Copper(II) interactions with nonsteroidal antiinflammatory agents. 2. Anthranilic acid as a potential (OH)-O-center dot-inactivating ligand. J Inorg Biochem 68, 27-38.
49. Halova-Lajoie B, Brumas W, Fiallo MML, &, Berthon G, (2006) Copper(II) interactions with non-steroidal anti-inflammatory agents. III-3-Methoxyanthranilic acid as a potential (OH)-O-center dot-inactivating ligand: a quantitative investigation of its copper handling role in vivo. J Inorg Biochem 100, 362-373.
50. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, et al. (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855.
51. Heyes MP, Mefford IN, Quearry BJ, Dedhia M, &, Lackner A, (1990) Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected Rhesus Macaques: relationship to clinical and viral status. Ann Neurol 27, 666-675.
52. Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Lee K, Bhalla RB, Der M, &, Markey SP, (1992) Inter-relationships between neuroactive kynurenines, neopterin and β2-microglobulin in CSF and serum of HIV-1 infected patients. J Neuroimmunol 40, 71-80.
53. Behan WMH, &, Stone TW, (2000) Role of kynurenines in the neurotoxic actions of kainic acid. Br J Pharmacol 129, 1764-1770.
54. Rover S, Cesura AM, Hugenin P, Kettler R, &, Szente A, (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40, 4378-4385.
55. Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, &, Phillips RS, (2005) Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect Immun 73, 5249-5251.
56. Rodgers J, Stone TW, Barratt MP, Bradley B, &, Kennedy PG, (2009) Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain 132, 1259-1267.
57. Lees GJ, (1993) The possible contribution of microglia and macrophages to delayed neuronal death after ischemia. J Neurol Sci 114, 119-122.
58. Baratte S, Molinari A, Veneroni O, Speciale C, Benatti L, &, Salvati P, (1998) Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia. Mol Brain Res 59, 50-57.
59. Shear DA, Dong J, Haik-Oreguer KL, Bazzett TJ, Albin RL, &, Dunbar GL, (1998) Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Exp Neurol 150, 305-311.
60. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, &, Dunbar GL, (1998) Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 22, 1217-1240.
61. Storey E, Cipolloni PB, Ferrante RJ, Kowall NW, &, Beal MF, (1994) Movement disorder following excitotoxin lesions in primates. Neuroreport 5, 1259-1261.
62. Burns LH, Pakzaban P, Deacon TW, Brownell AL, Tatter SB, Jenkins BG, &, Isacson O, (1995) Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 64, 1007-1017.
63. Harrison BL, Baron BM, Cousino DM, &, McDonald IA, (1990) 4-[(carboxymethyl)oxy]-5,7-dichloroquinoline-2-carboxylic and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid-new antagonists of the strychnine-insensitive glycine binding-site on the N-methyl-d-aspartate receptor complex. J Med Chem 33, 3130-3132.
64. Baron BM, Harrison BL, McDonald IA, Meldrum BS, Palfreyman MG, Salituro FG, Siegel BW, Slone AL, Turner JP, &, White HS, (1992) Potent indoleline and quinoline-containing N-methyl-d-aspartate antagonists acting at the strychnine-insensitive glycine binding-site. J Pharmacol Exp Ther 262, 947-956.
65. Carling RW, Leeson PD, Moore KW, Moyes CR, Duncton M, Hudson ML, Baker R, Foster AC, Grimwood S, Kemp JA, et al. (1997) 4-substituted-3-phenylquinolin- 2(1H)-ones: acidic and nonacidic glycine site N-methyl-d-aspartate antagonists with in vivo activity. J Med Chem 40, 754-765.
66. Salituro FG, Harrison BL, Baron BB, Nyce PL, Stewart KT, &, McDonald IA, (1990) 3-(2-carboxyindol-3-yl)propionic acid-derivatives-antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-d-aspartate receptor complex. J Med Chem 33, 2944-2946.
67. Cai SX, Zhou ZL, Huang JC, Whittemore ER, Egbuwoku ZO, Hawkinson JE, Woodward RM, Weber E, &, Keana JFW, (1996) Structure-activity relationships of 4-hydroxy-3-nitroquinolin-2(1H)-ones as novel antagonists at the glycine site of N-methyl-d-aspartate receptors. J Med Chem 39, 4682-4686.
68. Bristow LJ, Flatman KL, Hutson PH, Kulagowski JJ, Leeson PD, Young L, &, Tricklebank MD, (1996) The atypical neuroleptic profile of the glycine/N-methyl-d-aspartate receptor antagonist, L-701,324, in rodents. J Pharmacol Exp Therap 277, 578-585.
69. Takano K, Tatlisumak T, Formato JE, Carano RAD, Bergmann AG, Pullan LM, Bare TM, Sotak CH, &, Fisher M, (1997) Glycine site antagonist attenuates infarct size in experimental focal ischemia-postmortem and diffusion mapping studies. Stroke 28, 1255-1262.
70. Jackson PF, Davenport TW, Garcia L, McKinney JA, Melville MG, Harris GG, Chapdelaine MJ, Damewood JR, Pullan LM, &, Goldstein JM, (1995) Synthesis and biological activity of a series of 4-aryl substituted benz[b]azepines: antagonists at the strychnine-insensitive glycine site. Bioorg Med Chem Lett 5, 3097-3100.
71. Hokari M, Wu H-Q, Schwarcz R, &, Smith QR, (1996) Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport 8, 15-18.
72. Moore LW, Leeson PD, Carling RW, Tricklebank MD, &, Singh L, (1993) Anticonvulsant activity of glycine-site NMDA antagonists. 1: 2-carboxyl prodrugs of 5,7-dichlorokynurenic acid. Bioorg Med Chem Lett 3, 61-64.
73. Connick JH, Heywood GC, Sills GJ, Thompson GG, Brodie MJ, &, Stone TW, (1992) Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen Pharmacol 23, 235-239.
74. Russi P, Alesiani M, Lombardi G, Davolio P, Pellicciari R, &, Moroni F, (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J Neurochem 59, 2076-2080.
75. Moroni F, Russi P, Gallo-Mezo MA, Moneti G, &, Pellicciari RJ, (1991) Modulation of quinolinic and kynurenic acid content in the rat-brain-effects of endotoxins and nicotinylalanine. J Neurochem 57, 1630-1635.
76. Pellicciari R, Natalini B, Costantino G, Mahmoud MR, Mattoli L, Sadeghpour BM, Moroni F, Chiarugi A, &, Carpenedo R, (1994) Modulation of the kynurenine pathway in search for new neuroprotective agents-synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J Med Chem 37, 647-655.
77. Natalini B, Mattoli L, Pellicciari R, Carpenedo R, Chiarugi A, &, Moroni F, (1995) Synthesis and activity of enantiopure (s)(m-nitrobenzoyl) alanine, a potent kynurenine-3-hydroxylase inhibitor. Bioorg Med Chem Lett 5, 1451-1454.
78. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, &, Moroni F, (1995) Comparison of the neurochemical and behavioral-effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem 65, 1176-1183.
79. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, &, Schwarcz R, (1996) (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315, 263-267.
80. Walsh JL, Todd WP, Carpenter BK, &, Schwarcz R, (1991) 4-halo-3-hydroxyanthranilic acids-potent competitive inhibitors of 3-hydroxy-anthranilic acid oxygenase in vitro. Biochem Pharmacol 42, 985-990.
81. Naritsin DB, Saito K, Markey SP, &, Heyes MP, (1995) Metabolism of l-tryptophan to kynurenate and quinolinate in the central-nervous-system-effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. J Neurochem 65, 2217-2226.